Compugen Q1 Earnings Call Highlights
Key takeaways
- On the company’s first-quarter earnings call, President and Chief Executive Officer Dr.
- → 3 Crucial Aerospace Component Makers That Analysts Love
- → 3 Stocks to Own If Gas Prices Keep Rising
Compugen Q1 Earnings Call Highlights Market Beat Mon, May 18, 2026 at 9:08 PM GMT+7 6 min read CGEN AZN GILD Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs.
On the company’s first-quarter earnings call, President and Chief Executive Officer Dr. Eran Ophir said 2026 is “shaping up to be a significant year” for Compugen as it advances COM701, its wholly owned antibody targeting PVRIG, and monitors progress on partnered assets with AstraZeneca and Gilead.
→ 3 Crucial Aerospace Component Makers That Analysts Love